New Biomarkers in Pancreatic Cancer Using EXPEL Concept

Recruiting Observational Study
Oncology
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
200 (estimated)
Sponsor
University Hospital, Montpellier · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The investigators recently engineered a novel biomarker discovery approach that is non-destructive and fully compatible with OMICS profiling as well as routine clinical procedures (5). The latter approach - termed EXPEL - mines the interstitial tissue fluid that is the richest source of soluble, undiluted and uncontaminated biomarkers. The method notably gives access to proteins, metabolites, RNA,…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patient with pancreatic mass and suspicion of pancreatic ductal adenocarcinoma requiring endoscopic ultrasound with fine needle biopsy or surgery * Patient ≥18 years old * Patient naïve of any treatment of Pancreatic cancer Exclusion Criteria: * Patient who reject the study …
Contacts

REGIS SOUCHE, MD

467337072

fr-souche@chu-montpellier.fr

CONTACT

Jean-Michel Fabre, MD, PhD

467337072

jm-fabre@chu-montpellier.fr

CONTACT